Vaccines

We developed the CO-CoVac-01 vaccine candidate against COVID-19 by using an innovative nanoparticle-based platform. CO-CoVac-01 mimics SARS-CoV-2 particles to deliver safe and robust protection.

Name Target Stage development pre-clinical clinical trial
CO-CoVac-01 SARS CoV-2       development

A novel coronavirus SARS-CoV-2, which causes severe respiratory disease COVID-19 is a global threat. By the end of 2020 coronavirus caused 1.500.000 deaths . A potent vaccine that guarantees long-lasting immunity is desperately needed.

We use advanced biochemical engineering to produce nanoparticle vaccine CO-CoVac-01 against COVID-19. The components of the vaccine ensure ultimate protection and safety profile, resulting in prolonged immunity against a broad range of coronavirus infections. CO-CoVac-01 is a next-generation vaccine that expands the protection repertoire beyond the SARS-CoV-2 Spike protein, which is used in first-generation technologies.

 

Contact: biotech@cobik.si

Pipeline

COBIK is aimed to address the most pressing health challenges of the 21st century: antibiotic resistance and emerging viral diseases. Our pipeline is focused on bacteriophage-based solutions and viral vaccines.

READ MORE

Services

COBIK provides development of challenging bioprocess workflows, non-GMP manufacturing capabilities and complete project management expertise.

READ MORE

References

COBIK is a reliable partner to biopharma industry, academia and innovation ecosystem. Our drive for excellence is exemplified in track record of industrial services, patents, scientific publications and collaborations.

READ MORE

Outreach

We are determined to give back to our local community. Through public outreach events COBIK promotes science to school children and sparks curiosity in people of all ages.

READ MORE
cobik

Centre of Excellence for Biosensors, Instrumentation and Process Control

Mirce 21

SI-5270 Ajdovščina

info@cobik.si

About